Aravali Pharma

Aravali Pharma is a biotechnology company dedicated to developing novel antimicrobial peptides (AMPs) to address the global threat of multi-drug resistant bacterial infections and sepsis. The company's lead asset, ARV-1502, is a proline-rich antimicrobial peptide that targets the bacterial chaperone protein DnaK, effectively inhibiting bacterial protein folding and replication. Unlike conventional antibiotics, Aravali's therapeutic approach combines direct pathogen neutralization with beneficial immune system modulation. The company utilizes a virtual research and development model, leveraging deep expertise in peptide chemistry and collaborations with academic institutions. Aravali's platform aims to provide life-saving treatments for patients with limited options due to antibiotic resistance. The company continues to advance its pipeline through strategic partnerships and federal research grants.